Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project.
Diego Santos García, Marta Blázquez-Estrada, Matilde Calopa, Francisco Escamilla-Sevilla, Eric Freire, Pedro J García Ruiz, Francisco Grandas, Jaime Kulisevsky, Lydia López-Manzanares, Juan Carlos Martínez Castrillo, Pablo Mir, Javier Pagonabarraga, Francisco Pérez-Errazquin, José María Salom, Beatriz Tijero, Francesc Valldeoriola, Rosa Yáñez, Arantxa Avilés, María-Rosario Luquín
Author Information
Diego Santos García: Department of Neurology, Complexo Universitario de A Coruña (CHUAC), C/As Xubias 84, 15006 A Coruña, Spain. ORCID
Marta Blázquez-Estrada: Department of Neurology, Hospital Universitario Central de Asturias, Avenida de Roma s/n, 33011 Oviedo, Spain. ORCID
Francisco Escamilla-Sevilla: Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs. Granada, 18013 Granada, Spain. ORCID
Eric Freire: Departamento de Neurología, Hospital IMED Elche, Calle Max Planck 3, 03203 Elche, Spain.
Pedro J García Ruiz: Servicio de Neurología, Fundación Jiménez Díaz, Avda Reyes Católicos 2, 28040 Madrid, Spain.
Francisco Grandas: Servicio de Neurología, Hospital Gregorio Marañón, Calle del Dr. Esquerdo 46, 28007 Madrid, Spain.
Jaime Kulisevsky: Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
Lydia López-Manzanares: Servicio de Neurología, Hospital de la Princesa, Calle de Diego de León 62, 28006 Madrid, Spain.
Juan Carlos Martínez Castrillo: Servicio de Neurología, IRYCIS, Hospital Universitario Ramón y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain. ORCID
Pablo Mir: Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
Javier Pagonabarraga: Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
Francisco Pérez-Errazquin: Servicio de Neurología, Hospital Virgen de la Victoria, Campus de Teatinos, S/N, 29010 Málaga, Spain.
José María Salom: Servicio de Neurología, Hospital Clínico Universitario de Valencia, Avda Blasco Ibañez No. 17, 46010 Valencia, Spain.
Francesc Valldeoriola: Parkinson's Disease and Movement Disorders Unit-Neurology Service, Hospital Clinic Barcelona, Universitat de Barcelona & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Casanova 170, 08036 Barcelona, Spain.
Rosa Yáñez: Servicio de Neurología, Complejo Hospitalario Universitario de Ourense, Ramon Puga Noguerol 54, 32005 Ourense, Spain.
Arantxa Avilés: Departamento Médico, Zambon S.A.U. C/Maresme, 5 Pol. Ind. Can Bernades-Subirà, 08130 Barcelona, Spain.
María-Rosario Luquín: Departamento de Neurología, Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Avenida de Pio XII 36, 31008 Pamplona, Spain.
Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
